Insomnia Market By Therapy Type (Pharmacological Therapy and Non Pharmacological Therapy), By Drug Formulation (Capsules and Tablets), By Type of Diseases (Poor Quality of Sleep and Sleep Maintenance), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

Insomnia is a disorder characterized by lack of sleep or inability to sleep. People with insomnia often experience fatigue, low energy, difficulty concentrating, mood disturbances, and decreased performance overall. Insomnia-related conditions are caused due to disruption in circadian rhythm, chronic pain, hyperthyroidism, menopause, and psychological stress. Excessive use of drugs, such as caffeine, alcohol, and nicotine could also lead to insomnia.Insomnia Market accounted for US$ 2.76 billion in 2020 and is estimated to be US$ 4.62 billion by 2030 and is anticipated to register a CAGR of 5.0%.

Surging number of insomnia patient

Surging number of insomnia patient across the globe is the primary factor driving the market. Technological advances in the treatment drugs are also fuelling the target market growth currently. In addition, increasing number of people working in shifts and stressful conditions is also supporting the global market growth.

Lack of education and awareness

However, lack of education and awareness about the disorder is a major restraining factor for the growth of the market. Factors like presence of large undiagnosed insomnia population pool and untapped markets in developing economies present lucrative opportunities for the market growth.

Insomnia market has been segmented into therapy type drug formulation, and region.

On the basis of therapy type, insomnia market has been bifurcated into pharmacological therapy and non-pharmacological therapy. Non-pharmacological therapy is further segmented into hypnotherapy, cognitive behavioral therapy, medical devices, and other non-pharmacological therapy. Pharmacological therapy is further segmented into prescription sleep aids and over-the-counter sleep aids. Based on drug formulation, target market is classified into capsules and tablets. According to type of disease, global market is segmented into poor quality of sleep and sleep maintenance.

Regional Insights:

Based on region, the insomnia market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America region is dominating the global market as it accounts for the highest percentage of insomnia-affected patients among all regions. North America market is followed by Europe, owing to increasing stress among the population in these regions. Asia-Pacific, Middle East, and Africa markets are anticipated to have the least target market growth over the forecast period.

Detailed Segmentation:

Insomnia Market, By Region:

• North America
  • Middle East & Africa
    • Middle East & Africa Insomnia Market, By Therapy Type
    • Middle East & Africa Insomnia Market, By Drug Formulation
    • Middle East & Africa Insomnia Market, By Type of Disease
    • Middle East & Africa Insomnia Market, By Country
      • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • Latin America Insomnia Market, By Therapy Type
    • Latin America Insomnia Market, By Drug Formulation
    • Latin America Insomnia Market, By Type of Disease
    • Latin America Insomnia Market, By Country
      • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • Asia Pacific Insomnia Market, By Therapy Type
    • Asia Pacific Insomnia Market, By Drug Formulation
    • Asia Pacific Insomnia Market, By Type of Disease
    • Asia Pacific Insomnia Market, By Country
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • Europe Insomnia Market, By Therapy Type
    • Europe Insomnia Market, By Drug Formulation
    • Europe Insomnia Market, By Type of Disease
    • Europe Insomnia Market, By Country
      • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • North America Insomnia Market, By Therapy Type
  • North America Insomnia Market, By Drug Formulation
  • North America Insomnia Market, By Type of Disease
  • North America Insomnia Market, By Country
    • The U.S.
    • Canada

Key players operating in the insomnia market include Eisai, Co., Pfizer, Inc., Merck & Co Inc., Sanofi SA, Takeda Pharmaceutical Company, Meda Consumer Healthcare Inc., Pernix Therapeutics, Purdue Pharma L.P., Consumer Healthcare Inc., and Dainippon Sumitomo Pharma Ltd.

• Eisai, Co.
  • Dainippon Sumitomo Pharma Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  • Consumer Healthcare Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  • Purdue Pharma L.P.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  • Pernix Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  • Meda Consumer Healthcare Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  • Takeda Pharmaceutical Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  • Sanofi SA
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  • Merck & Co Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance